Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : NewAmsterdam Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Menarini’s Obicetrapib Trials Show Positive Phase 3 Data for Cholesterol Reduction
Details : TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2024
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : NewAmsterdam Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NewAmsterdam Pharma Announces Phase 3 BROADWAY Trial Data for Obicetrapib
Details : TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NewAmsterdam Doses First Patient in Phase 3 TANDEM Trial for Obicetrapib
Details : NewAmsterdam TA-8995 (obicetrapib) is a CETP inhibitor combined with Ezetimibe, under evaluation in Phase III trials for Heterozygous Familial Hypercholesterolemia and cardiovascular disease.
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NewAmsterdam Releases Phase 3 TANDEM Data for Obicetrapib-Ezetimibe in ASCVD Patients
Details : TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2024
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NewAmsterdam Pharma Completes Enrollment in Phase 3 TANDEM Trial for Obicetrapib
Details : TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 07, 2024
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rosuvastatin,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rosuzet is a combination of rosuvastatin is an inhibitor of HMG CoA-reductase, the rate-limiting enzyme that converts the precursor of cholesterol and ezetimibe, a sterol transporter, NPC1L1, which is involved in the intestinal uptake of cholesterol.
Product Name : Rosuzet
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2023
Lead Product(s) : Rosuvastatin,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor having the potential for lowering LDL-C, if approved. It is currently being investigated in combination with ezetimibe as an adjunct to high-intensity statin...
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 17, 2023
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Obicetrapib (TA-8995) is an oral, low-dose and once-daily CETP inhibitor, initially in development for patients at high risk for cardiovascular disease as an adjunct to maximally tolerated statin therapy, both as a monotherapy and in a fixed-dose combina...
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2022
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ROSE2 study evaluates obicetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor, in combination with ezetimibe, a cholesterol absorption inhibitor, in patients who are currently receiving high-intensity statin therapy.
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inclisiran,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Leqvio®* (Inclisiran) Reduced LDL-C in People who Are Overweight or Obese
Details : Treatment emergent adverse events (TEAEs) at the injection site were more frequent with Leqvio, but all were mild or moderate. The effect of Leqvio on cardiovascular morbidity and mortality has not been determined.
Product Name : Leqvio
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 11, 2021
Lead Product(s) : Inclisiran,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable